Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults

Empros Pharma AB · Phase 3 · Completed · Enrollment 638

NCT01755676

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Orlistat 60 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Orlistat 60 mg: endpoint not reported
  • Placebo: endpoint not reported